天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型)
Instant ELISA Kit for Aspartate Aminotransferase (AST)
cCAT; AAT; ASAT; SGOT; GOT1; Cysteine transaminase, cytoplasmic; Transaminase A; Aspartate Transaminase 1,Cytoplasmic; Glutamic-Oxaloacetic Transaminase 1,Soluble
- 編號(hào)UIEB214Mu
- 物種Mus musculus (Mouse，小鼠) 相同的名稱(chēng)，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)1h, 10min
- 檢測(cè)范圍1.56-100ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.55ng/mL.
- 樣本類(lèi)型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 1724 ¥ 2463 ¥ 11084 ¥ 20936 ¥ 172410
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 79-96 | 86 |
| EDTA plasma(n=5) | 85-99 | 90 |
| heparin plasma(n=5) | 80-95 | 84 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 92-105% | 86-103% | 95-103% | 92-101% |
| EDTA plasma(n=5) | 98-105% | 93-101% | 88-104% | 81-96% |
| heparin plasma(n=5) | 87-101% | 80-99% | 83-98% | 80-89% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C溫育30分鐘;
3. 甩干，加檢測(cè)溶液A100µL，37°C溫育30分鐘;
4. 洗板3次；
5. 加檢測(cè)溶液B100µL， 37°C孵育10分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10－20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPB214Mu01 | 天冬氨酸轉(zhuǎn)氨酶(AST)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPB214Mu02 | 天冬氨酸轉(zhuǎn)氨酶(AST)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPB214Mu01 | 天冬氨酸轉(zhuǎn)氨酶(AST)活性蛋白 | Cell?culture;?Activity?Assays. |
| UPAB214Mu01 | 天冬氨酸轉(zhuǎn)氨酶(AST)多克隆抗體 | WB; IHC |
| UPAB214Mu02 | 天冬氨酸轉(zhuǎn)氨酶(AST)多克隆抗體 | IHC |
| ULAB214Mu81 | 天冬氨酸轉(zhuǎn)氨酶(AST)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| ULAB214Mu71 | 天冬氨酸轉(zhuǎn)氨酶(AST)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| UMAB214Mu22 | 天冬氨酸轉(zhuǎn)氨酶(AST)單克隆抗體 | IHC |
| UMAB214Mu21 | 天冬氨酸轉(zhuǎn)氨酶(AST)單克隆抗體 | WB; IHC |
| UMEB214Mu | 天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| UIEB214Mu | 天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USEB214Mu | 天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMB214Mu | 天冬氨酸轉(zhuǎn)氨酶(AST)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UPSB214Mu01 | 天冬氨酸轉(zhuǎn)氨酶(AST)抗體對(duì) | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
| UKSB214Mu01 | 天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Kidney International | Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms [PubMed: PMC3612362] |
| Proceedings of the National Academy of Sciences | Pathogenesis of emerging severe fever with thrombocytopenia syndrome virus in C57/BL6 mouse model [PubMed: PMC3382536] |
| African Journal of Pharmacy and Pharmacology | Protective effect of Panax ginseng against N-acetyl-p-aminophenol-induced hepatotoxicity in rats [Academicjournals: Source] |
| Kidney International | Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and-independent mechanisms [Pubmed: 23325074] |
| European Journal of Pharmacology | Protective effect of Et-1 receptor antagonist bosentan on paracetamol induced acute liver toxicity in rats [ScienceDirect: S0014299914000235] |
| Journal of Immunology | The P2X1 Receptor Is Required for Neutrophil Extravasation during Lipopolysaccharide-Induced Lethal Endotoxemia in Mice [Pubmed:25480563] |
| Gastroenterol Res Pract | Assessing the Effect of Leptin on Liver Damage in Case of Hepatic Injury Associated with Paracetamol Poisoning [PubMed: 26697061] |
| Gastroenterol Res Pract. | Advanced Studies in Clinical and Experimental Research in Gastroenterology [Pubmed:26955389] |
| Scientific Reports | Adiponectin?protects?the?rats?liver?against?chronic?intermittent?hypoxia?induced?injury?throughAMP-activated?protein?kinase?pathway. [pubmed:27678302] |
| ?Biochimica et Biophysica Acta (BBA)-General Subjects | Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats [pubmed:28341485] |
| Scientific Reports | Deletion of MCP-1 Impedes Pathogenesis of Acid Ceramidase Deficiency [Pubmed:29379059] |
| FEBS?Open?Bio | A critical role of hepatitis B virus polymerase in cirrhosis, hepatocellular carcinoma, and steatosis [Pubmed:29321963] |
| BMC?Complementary and Alternative?Medicine? | Hepatoprotective activity of Erythrina× neillii leaf extract and characterization of its phytoconstituents [Pubmed: 28095910] |
| laboratory investigation | Hepatic pathology and altered gene transcription in a murine model of acid ceramidase deficiency [Pubmed: 31186526] |
| Brain Behavior and Immunity | Corticosterone-mediated microglia activation affects dendritic spine plasticity and motor learning functions in minimal hepatic encephalopathy [Pubmed: 31437533] |
| Biomed Research International | Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet [Pubmed: 32149099] |
| Nanomaterials | Biological Safety and Biodistribution of Chitosan Nanoparticles [Pubmed: 32340313] |
| European Journal of Biology | Effects of Tempol in Lipopolysaccharide-Induced Liver Injury [] |
| Pathogens | Antimalarial Effect of the Total Glycosides of the Medicinal Plant, Ranunculus japonicus [33925018] |
| Int Immunopharmacol | Taraxasterol mitigates Con A-induced hepatitis in mice by suppressing interleukin-2 expression and its signaling in T lymphocytes [34848154] |
| Acta Pharmacol Sin | NFAT inhibitor 11R-VIVIT ameliorates mouse renal fibrosis after ischemia-reperfusion-induced acute kidney injury [34937917] |
| J Magn Reson Imaging | Water Specific MRI T1 Mapping for Evaluating Liver Inflammation Activity Grades in Rats With Methionine‐Choline‐Deficient Diet‐Induced Nonalcoholic Fatty Liver?… [Pubmed:35212074] |
| Medcomm | Blockade of mIL‐6R alleviated lipopolysaccharide‐induced systemic inflammatory response syndrome by suppressing NF‐κB‐mediated Ccl2 expression and?… [Pubmed:35548710] |
| International Immunopharmacology | Dimethyl fumarate ameliorates autoimmune hepatitis in mice by blocking NLRP3 inflammasome activation [Pubmed:35605433] |
